Should I Buy TBI? TBI 2026 Analysis

Should You Buy TrueBlue Inc (TBI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

4.920

1 Day change

2.93%

52 Week Range

8.550

Analysis Updated At

2026/01/26

TrueBlue Inc. (TBI) is not a strong buy at this time for a beginner investor with a long-term strategy. While the company has shown revenue growth in the latest quarter, its declining net income, EPS, and gross margin, coupled with no strong trading signals or positive catalysts, suggest that the stock lacks immediate upside potential. The technical indicators are neutral, and the options data does not indicate significant bullish sentiment. For a long-term investor, it may be better to wait for clearer signs of financial recovery or stronger market sentiment.

Technical Analysis

The MACD is positive but contracting, RSI is neutral at 60.983, and moving averages are converging. The stock is trading near its pivot level of 5.057, with resistance at 5.491 and support at 4.624. Overall, the technical indicators do not suggest a strong trend in either direction.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Analysts maintain an Outperform rating, citing margin-driven and organic growth beats.

Neutral/Negative Catalysts

Net income dropped by 74.91% YoY, EPS fell by 76.92%, and gross margin declined by 12.74%. No recent news or significant insider/hedge fund trading activity. Stock trend analysis suggests a potential decline in the next month.

Financial Performance

In Q3 2025, revenue increased to $431.27M (up 12.79% YoY), but net income dropped to -$1.92M (down 74.91% YoY), EPS fell to -0.06 (down 76.92% YoY), and gross margin decreased to 21.24% (down 12.74% YoY).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

BMO Capital lowered the price target from $8 to $6 but maintained an Outperform rating, citing optimism about stabilization in end markets despite challenges in the staffing sector.

1 Analyst Rating

Wall Street analysts forecast TBI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TBI is 6 USD with a low forecast of 6 USD and a high forecast of 6 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 4.780

Low

Averages

High

Current: 4.780

Low

Averages

High

BMO Capital

Outperform

NULL

downgrade

$8 -> $6

AI Analysis

2025-11-05

Reason

BMO Capital

Price Target

$8 -> $6

AI Analysis

2025-11-05

downgrade

Outperform

NULL

Reason

BMO Capital lowered the firm's price target on TrueBlue to $6 from $8 and keeps an Outperform rating on the shares. The company delivered a sizable margin-driven and organic-growth driven beat to consensus, and while many staffing names have been under pressure, TrueBlue seemed to fare better this quarter, the analyst tells investors in a research note. BMO adds it is cautiously optimistic that this "Canary in the Coal mine" will continue to inflect positively as conditions continue to stabilize within its end markets.

TBI Should I Buy

TBI Should I Buy

Should You Buy TrueBlue Inc (TBI) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch